Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation

Kartik Agusala, Adam Oesterle, Chiraag Kulkarni, Timothy Caprio, Haris Subacius, Rod Passman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present. Whether low-risk patients can be identified to safely allow outpatient initiation is unknown. Methods A single-center retrospective cohort study was performed on patients initiated with DF or SL. Risk factors for adverse events (AEs), defined as any arrhythmia or electrocardiogram change requiring dose reduction or cessation, were identified. Results Of 329 patients, 227 (69%) received SL and 102 (31%) DF. The cohort had a mean age of 63 ± 13 years; 70% of patients were male and had a baseline QTc of 440 ± 37 ms. A total of 105 AEs occurred in 92 patients: QTc prolongation or ventricular tachyarrhythmia in 70 patients (67% of AEs), bradyarrhythmias in 35 patients (33% of AEs), with some experiencing both AE types. Ventricular arrhythmias were seen in 23 patients (7%) and torsades de pointes in one (0.3%). Total AE rates were similar between drugs (P = 0.09); however, DF patients had more QTc prolongation or ventricular arrhythmias (P = 0.001). In SL patients, there were no predictors for QTc prolongation or ventricular proarrhythmia. In DF patients, higher baseline QTc interval (odds ratio = 1.64/25 ms, P = 0.01) was an independent predictor of QTc prolongation or ventricular proarrhythmias. For patients without proarrhythmia risk factors, overall AE rate was 26%. Conclusions In conclusion, AEs are common during DF and SL initiation but rarely severe in hospitalized inpatients. Baseline QTc predicts AEs for DF patients only and AE are common even in "low-risk" patients. These results support in-hospital drug initiation for all DF and SL patients.

Original languageEnglish (US)
Pages (from-to)490-498
Number of pages9
JournalPACE - Pacing and Clinical Electrophysiology
Volume38
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Sotalol
Atrial Fibrillation
Therapeutics
Cardiac Arrhythmias
dofetilide
Inpatients
Torsades de Pointes
Anti-Arrhythmia Agents
Bradycardia

Keywords

  • antiarrhythmic drugs
  • atrial fibrillation
  • dofetilide
  • sotalol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. / Agusala, Kartik; Oesterle, Adam; Kulkarni, Chiraag; Caprio, Timothy; Subacius, Haris; Passman, Rod.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 38, No. 4, 01.04.2015, p. 490-498.

Research output: Contribution to journalArticle

Agusala, Kartik ; Oesterle, Adam ; Kulkarni, Chiraag ; Caprio, Timothy ; Subacius, Haris ; Passman, Rod. / Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. In: PACE - Pacing and Clinical Electrophysiology. 2015 ; Vol. 38, No. 4. pp. 490-498.
@article{d24062db8640408a96becd8becfa213f,
title = "Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation",
abstract = "Background Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present. Whether low-risk patients can be identified to safely allow outpatient initiation is unknown. Methods A single-center retrospective cohort study was performed on patients initiated with DF or SL. Risk factors for adverse events (AEs), defined as any arrhythmia or electrocardiogram change requiring dose reduction or cessation, were identified. Results Of 329 patients, 227 (69{\%}) received SL and 102 (31{\%}) DF. The cohort had a mean age of 63 ± 13 years; 70{\%} of patients were male and had a baseline QTc of 440 ± 37 ms. A total of 105 AEs occurred in 92 patients: QTc prolongation or ventricular tachyarrhythmia in 70 patients (67{\%} of AEs), bradyarrhythmias in 35 patients (33{\%} of AEs), with some experiencing both AE types. Ventricular arrhythmias were seen in 23 patients (7{\%}) and torsades de pointes in one (0.3{\%}). Total AE rates were similar between drugs (P = 0.09); however, DF patients had more QTc prolongation or ventricular arrhythmias (P = 0.001). In SL patients, there were no predictors for QTc prolongation or ventricular proarrhythmia. In DF patients, higher baseline QTc interval (odds ratio = 1.64/25 ms, P = 0.01) was an independent predictor of QTc prolongation or ventricular proarrhythmias. For patients without proarrhythmia risk factors, overall AE rate was 26{\%}. Conclusions In conclusion, AEs are common during DF and SL initiation but rarely severe in hospitalized inpatients. Baseline QTc predicts AEs for DF patients only and AE are common even in {"}low-risk{"} patients. These results support in-hospital drug initiation for all DF and SL patients.",
keywords = "antiarrhythmic drugs, atrial fibrillation, dofetilide, sotalol",
author = "Kartik Agusala and Adam Oesterle and Chiraag Kulkarni and Timothy Caprio and Haris Subacius and Rod Passman",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/pace.12586",
language = "English (US)",
volume = "38",
pages = "490--498",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation

AU - Agusala, Kartik

AU - Oesterle, Adam

AU - Kulkarni, Chiraag

AU - Caprio, Timothy

AU - Subacius, Haris

AU - Passman, Rod

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present. Whether low-risk patients can be identified to safely allow outpatient initiation is unknown. Methods A single-center retrospective cohort study was performed on patients initiated with DF or SL. Risk factors for adverse events (AEs), defined as any arrhythmia or electrocardiogram change requiring dose reduction or cessation, were identified. Results Of 329 patients, 227 (69%) received SL and 102 (31%) DF. The cohort had a mean age of 63 ± 13 years; 70% of patients were male and had a baseline QTc of 440 ± 37 ms. A total of 105 AEs occurred in 92 patients: QTc prolongation or ventricular tachyarrhythmia in 70 patients (67% of AEs), bradyarrhythmias in 35 patients (33% of AEs), with some experiencing both AE types. Ventricular arrhythmias were seen in 23 patients (7%) and torsades de pointes in one (0.3%). Total AE rates were similar between drugs (P = 0.09); however, DF patients had more QTc prolongation or ventricular arrhythmias (P = 0.001). In SL patients, there were no predictors for QTc prolongation or ventricular proarrhythmia. In DF patients, higher baseline QTc interval (odds ratio = 1.64/25 ms, P = 0.01) was an independent predictor of QTc prolongation or ventricular proarrhythmias. For patients without proarrhythmia risk factors, overall AE rate was 26%. Conclusions In conclusion, AEs are common during DF and SL initiation but rarely severe in hospitalized inpatients. Baseline QTc predicts AEs for DF patients only and AE are common even in "low-risk" patients. These results support in-hospital drug initiation for all DF and SL patients.

AB - Background Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present. Whether low-risk patients can be identified to safely allow outpatient initiation is unknown. Methods A single-center retrospective cohort study was performed on patients initiated with DF or SL. Risk factors for adverse events (AEs), defined as any arrhythmia or electrocardiogram change requiring dose reduction or cessation, were identified. Results Of 329 patients, 227 (69%) received SL and 102 (31%) DF. The cohort had a mean age of 63 ± 13 years; 70% of patients were male and had a baseline QTc of 440 ± 37 ms. A total of 105 AEs occurred in 92 patients: QTc prolongation or ventricular tachyarrhythmia in 70 patients (67% of AEs), bradyarrhythmias in 35 patients (33% of AEs), with some experiencing both AE types. Ventricular arrhythmias were seen in 23 patients (7%) and torsades de pointes in one (0.3%). Total AE rates were similar between drugs (P = 0.09); however, DF patients had more QTc prolongation or ventricular arrhythmias (P = 0.001). In SL patients, there were no predictors for QTc prolongation or ventricular proarrhythmia. In DF patients, higher baseline QTc interval (odds ratio = 1.64/25 ms, P = 0.01) was an independent predictor of QTc prolongation or ventricular proarrhythmias. For patients without proarrhythmia risk factors, overall AE rate was 26%. Conclusions In conclusion, AEs are common during DF and SL initiation but rarely severe in hospitalized inpatients. Baseline QTc predicts AEs for DF patients only and AE are common even in "low-risk" patients. These results support in-hospital drug initiation for all DF and SL patients.

KW - antiarrhythmic drugs

KW - atrial fibrillation

KW - dofetilide

KW - sotalol

UR - http://www.scopus.com/inward/record.url?scp=84926148876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926148876&partnerID=8YFLogxK

U2 - 10.1111/pace.12586

DO - 10.1111/pace.12586

M3 - Article

VL - 38

SP - 490

EP - 498

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 4

ER -